Ciprofloxacin has poor/no coverage of S. pneumoniae and should not be used routinely in AECB. Because it retains the best activity against Pseudomonas aeruginosa, ciprofloxacin may have a role in end stage disease with/without bronchiectasis, when there has been documentation of colonization/infection with this organism. Empiric S. pneumoniae coverage still recommended.